As described earlier, single-agent PD-(L)1 inhibitor therapies generate lasting antitumor response in subgroups of patients with advanced HCC18, 19, 172but do not demonstrate a significant survival benefit for the overall treatment population compared with tyrosine kinase inhibitors.20, 173Combining ICI with other, already existing antitumor agents for primary liver cancer represents an accessible choice to overcome primary resistance to ICI therapy (Table 2). Here, CD274 is linked to liver cancer.